KJ-C2634

KJ-C2634 is an investigational in vivo chimeric antigen receptor (CAR) T-cell therapy being developed by CARsgen Therapeutics. Unlike traditional ex vivo CAR-T therapies that require complex manufacturing of patient cells outside the body, KJ-C2634 is designed to generate CAR-T cells directly within the patient's body. The therapy specifically targets Claudin18.2 (CLDN18.2), a tight junction protein that is frequently overexpressed in various solid tumors, particularly gastric and gastroesophageal junction adenocarcinomas. By targeting CLDN18.2, KJ-C2634 aims to provide a more accessible and potentially more efficient treatment option for patients with these cancers. As of 2026, the program is in the pre-clinical stage of development.

Other names

KJ-C2634KJ-C-2634KJ-C 2634